Biohit Oyj (BIOBV.HE)
EUR 2.23
(-2.19%)
EUR 2.23
(-2.19%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.97 Million EUR | -43.75% |
| 2022 | 7.11 Million EUR | 20.24% |
| 2021 | 5.91 Million EUR | 49.42% |
| 2020 | 3.95 Million EUR | -40.63% |
| 2019 | 6.66 Million EUR | 3.51% |
| 2018 | 6.44 Million EUR | 14.2% |
| 2017 | 5.64 Million EUR | 34.13% |
| 2016 | 4.2 Million EUR | 31.53% |
| 2015 | 3.19 Million EUR | 31.08% |
| 2014 | 2.43 Million EUR | 39.29% |
| 2013 | 1.75 Million EUR | 140.52% |
| 2012 | 728 Thousand EUR | -97.6% |
| 2011 | 30.33 Million EUR | -4.72% |
| 2010 | 31.84 Million EUR | 10.2% |
| 2009 | 28.89 Million EUR | 2.74% |
| 2008 | 28.12 Million EUR | 7.95% |
| 2007 | 26.05 Million EUR | 4.29% |
| 2006 | 24.98 Million EUR | 8.73% |
| 2005 | 22.97 Million EUR | 8.77% |
| 2004 | 21.12 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.3 Million EUR | 0.0% |
| 2024 Q1 | 2.3 Million EUR | 53.33% |
| 2023 FY | 4 Million EUR | -43.75% |
| 2023 Q1 | 2.25 Million EUR | 181.25% |
| 2023 Q2 | 2.5 Million EUR | 11.11% |
| 2023 Q3 | 1.98 Million EUR | -20.72% |
| 2023 Q4 | 1.5 Million EUR | -24.32% |
| 2022 Q3 | 1.35 Million EUR | -41.04% |
| 2022 Q1 | 2.2 Million EUR | 175.0% |
| 2022 FY | 7.11 Million EUR | 20.24% |
| 2022 Q4 | 800 Thousand EUR | -41.0% |
| 2022 Q2 | 2.3 Million EUR | 4.55% |
| 2021 FY | 5.91 Million EUR | 49.42% |
| 2021 Q4 | 800 Thousand EUR | -54.48% |
| 2021 Q1 | 1.2 Million EUR | 500.0% |
| 2021 Q3 | 1.75 Million EUR | 685.83% |
| 2021 Q2 | -300 Thousand EUR | -125.0% |
| 2020 Q3 | 1.12 Million EUR | 225.44% |
| 2020 FY | 3.95 Million EUR | -40.63% |
| 2020 Q2 | -900 Thousand EUR | -205.88% |
| 2020 Q1 | 850 Thousand EUR | 70.0% |
| 2020 Q4 | -300 Thousand EUR | -126.57% |
| 2019 Q3 | 1.48 Million EUR | 64.83% |
| 2019 Q4 | 500 Thousand EUR | -66.3% |
| 2019 FY | 6.66 Million EUR | 3.51% |
| 2019 Q2 | 900 Thousand EUR | -51.35% |
| 2019 Q1 | 1.85 Million EUR | 10.75% |
| 2018 FY | 6.44 Million EUR | 14.2% |
| 2018 Q3 | 1.67 Million EUR | 7.77% |
| 2018 Q2 | 1.55 Million EUR | 0.0% |
| 2018 Q1 | 1.55 Million EUR | 1.97% |
| 2018 Q4 | 1.67 Million EUR | 0.0% |
| 2017 Q3 | 1.52 Million EUR | 16.92% |
| 2017 Q1 | 1.29 Million EUR | -18.75% |
| 2017 Q4 | 1.52 Million EUR | 0.0% |
| 2017 FY | 5.64 Million EUR | 34.13% |
| 2017 Q2 | 1.29 Million EUR | 0.0% |
| 2016 Q3 | 1.6 Million EUR | 52.38% |
| 2016 Q1 | 1.05 Million EUR | 111.27% |
| 2016 FY | 4.2 Million EUR | 31.53% |
| 2016 Q4 | 1.6 Million EUR | 0.0% |
| 2016 Q2 | 1.05 Million EUR | 0.0% |
| 2015 Q3 | 700 Thousand EUR | -46.15% |
| 2015 Q2 | 1.3 Million EUR | 62.5% |
| 2015 Q1 | 800 Thousand EUR | 25.2% |
| 2015 Q4 | 497 Thousand EUR | -29.0% |
| 2015 FY | 3.19 Million EUR | 31.08% |
| 2014 Q1 | 500 Thousand EUR | 42.45% |
| 2014 FY | 2.43 Million EUR | 39.29% |
| 2014 Q4 | 639 Thousand EUR | -8.71% |
| 2014 Q3 | 700 Thousand EUR | 16.67% |
| 2014 Q2 | 600 Thousand EUR | 20.0% |
| 2013 Q3 | 600 Thousand EUR | 50.0% |
| 2013 Q4 | 351 Thousand EUR | -41.5% |
| 2013 Q1 | 300 Thousand EUR | 134.38% |
| 2013 Q2 | 400 Thousand EUR | 33.33% |
| 2013 FY | 1.75 Million EUR | 140.52% |
| 2012 FY | 728 Thousand EUR | -97.6% |
| 2012 Q3 | 200 Thousand EUR | 0.0% |
| 2012 Q2 | 200 Thousand EUR | 0.0% |
| 2012 Q4 | 128 Thousand EUR | -36.0% |
| 2012 Q1 | 200 Thousand EUR | -97.08% |
| 2011 Q4 | 6.83 Million EUR | -5.03% |
| 2011 Q1 | 8.4 Million EUR | -24.62% |
| 2011 Q2 | 8.1 Million EUR | -3.57% |
| 2011 Q3 | 7.2 Million EUR | -11.11% |
| 2011 FY | 30.33 Million EUR | -4.72% |
| 2010 Q2 | 7.8 Million EUR | 5.41% |
| 2010 Q3 | 9.6 Million EUR | 23.08% |
| 2010 Q1 | 7.4 Million EUR | -27.92% |
| 2010 Q4 | 11.14 Million EUR | 16.08% |
| 2010 FY | 31.84 Million EUR | 10.2% |
| 2009 Q1 | 7 Million EUR | 0.0% |
| 2009 FY | 28.89 Million EUR | 2.74% |
| 2009 Q4 | 10.26 Million EUR | 26.74% |
| 2009 Q3 | 8.1 Million EUR | 14.08% |
| 2009 Q2 | 7.1 Million EUR | 1.43% |
| 2008 FY | 28.12 Million EUR | 7.95% |
| 2007 FY | 26.05 Million EUR | 4.29% |
| 2006 FY | 24.98 Million EUR | 8.73% |
| 2005 FY | 22.97 Million EUR | 8.77% |
| 2004 FY | 21.12 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Herantis Pharma Oyj | - EUR | -Infinity% |
| Nanoform Finland Oyj | 1.71 Million EUR | -131.507% |